MARKING CRITERIA

A. Technical (80 Marks)				
Sr. No.	**Parameters**	**Details**	**Maximum grade**	**Remarks**
1.	Product Registration	Category -A 1) US FDA 2) EMA (Europe source only) 3) MHRA UK 4) TGA Australia 5) PHARMAC. New Zeeland 6) PMDA Japan 7) Swiss-Medics Switzerland 45 8). Health Canada 9) HAS Singapore	45	
		Category -B 1) ANVIZ Brazil 2) CDSCO India 3) NPCB Malaysia 4) FDA South Korea 40 5). MOH Egypt 6) MOH Turkey 7) FDA China 8). ANMAT Argentina 9). DRA Pakistan 35 10). any other Authorities not mentioned in category-A	35	
2.	Bio-availability/Bio equivalence/ Bio similar certificate.	Whatever and wherever applicable	10	10 marks will be given in case where none is applicable for certain formula
3.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted item is drug. In case if the quoted item is generic the studies must be performed on the generic and not on the originator. (Must be an original research article).	In case the study is published in journal listed in HEC Journal Recognition System (HJRS) Database.	5 (Only if study is provided in CD.)	DOI or article title page copy is mandatory to provide (both in soft and hard form) and mentioned in format form.
		In case the study is published in journal NOT listed in HEC Journal Recognition System (HJRS) Database	0	
4.	Cold Chain Facility	Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP. PSQCA, and PCSIR	5	The procurement entity reserves the right to visit any cold chain facility for physical Inspection/ verification
		NON-Compliance to international reference standards or absence of cold chain requirement	0	Disqualification

CamScanner

MARKING CRITERIA

5.	Current GMP Certificate	Issued by authorities as mentioned in Category A as mentioned above in Sr. no. 1	5	Certificate should be attached with technical bid
		Issued by authorities as mentioned in Category B as mentioned above in Sr. no. 1	2	
6.	Past Performance (Last two years)	• Agha Khan University Hospital Karachi. • Shaukat Khanum Hospitals • Shifa International hospital Islamabad. • Atomic Energy Cancer Hospitals	5	Invoice proof clearly showing date and quantity of supply and also "Good performance Certificate" will be needed from the institute to which the supplies are made.
		Others	2	
B. Financial (20 Marks)				
7.	Financial status: (The price quoted must be the lowest quoted anywhere in Pakistan in the previous twelve months in case this is bound to refund the difference of the price to the procuring agency.)	**(Lowest Bid/Your Bid) x 20**		
C. Supplier Marks (05)				
8.	If Manufacturer or Importer submit bids	**05**		
	If Manufacturer or Importer submit bids via Distributor	**0**		

Total Technical score = 75
Total financial score = 20
Supplier Marks = 05
Total score: 100

Qualifying marks in technical: 45

General secretary, BPWS

CamScanner

TENDER FOR ANTI-CANCER MEDICINE PURCHASE FOR BINOR PATIENTS WELFARE SOCIETY (BPWS), PHARMACY.

Eligibility Criteria

01. All importers, manufacturers, and distributors must hold the applicable licenses and approvals required by the relevant authorities.

02. All importers/manufacturers or distributors must be listed on the Active Taxpayers List (ATL) of FBR.

Terms & Conditions

03. The invitation for Bids is open for all eligible/qualified manufacturers importers or their authorized agents in Pakistan for supply of anti-cancer medicine as per the attached sheet on competitive bidding of **single stage two envelopes procedure basis.**

04. The price quoted must be the lowest quoted anywhere in Pakistan like quoted in MCC.

05. Bidders are advised to submit their bids according to **prescribe format** which can be received from BPWS pharmacy along with bid documents Bids received on different formats, may not be considered.

06. Quotation must be accompanied with call deposit/ earnest money amounting **PKRs.500,000/- in favor of BPWS.**

07. The validity of tender should be for a period of 12 months from the date of awarding tender, which is extendable on mutual consents.

08. Supplier shall provide necessary Cheque acknowledgement receipt of payment made to them through crossed Cheque.

09. Payment will made on monthly basis, the amount of monthly payment to a particular supplier would depend on the sale of medicine of that particular supplier and payment from SLIC.

10. The supplier/firm having bad reputation/black list with any government 'organization etc. may not apply at all and will not be entertained.

11. Income Tax/GST as per rules of Govt shall be deducted on all supply.

12. The competent authority reserved the right to accept or reject any quotation/tender or part thereof without assigning any reason in writing.

13. The supplier will have to submit authorized distribution certificate from the concerned pharmaceutical at the time of tender.

CamScanner

TENDER FOR ANTI-CANCER MEDICINE PURCHASE FOR BINOR PATIENTS WELFARE SOCIETY (BPWS), PHARMACY.

14. The final selection will be made on the total final marks (Technical+ Financial base).
15. All medicines supplied shell be subject to the inspection by inspection office of pharmacist of this organization.
16. The price of medicine must be quoted in unit cost i.e. **per tab per capsule or per injection.**
17. The supplier will be responsible to maintain the cold chain of the medicines if applicable for any quality compromise due to cold chain breakage the supplier will be responsible.
18. While supplying the medicines only those medicine will be supplied which have the maximum expiry date available in the market and not less than 06 months All short expiry medicines will be replaced with fresh stock.
19. The amount of call deposit/ earnest money will be forfeited in case the firm/supplier fail to supply the medicines as per our specification requirement or violating any Bid terms & conditions.
20. **Passing marks in technical evaluation are 45 out of 80**
21. Winning firm will be bond to supply medicine within 72 hours, contrary BPWS pharmacy will go to next option.
22. BPWS will rank medicine as per given marking criteria. (Technical + Financial).
23. Marks for clinical study/trial documentation shall be awarded only if the relevant documents are submitted on CD.
24. Pre-bid meeting will be held to clarify important points and answer any question from bidder on - **15/10/2026 (12:30pm)** at BINOR auditorium. Those who want to clarify any of their queries can attend the meeting.

25. Last date for submission of bids is within 15 Days of tender publication on PPRA.

Note: Manufacturer or importers are encouraged to submit bids directly, and as such will be awarded additional 05 marks.

General Secretary, BPWS

CamScanner

BINOR Patients Welfare Society Bannu
Tender for FY 2026-27
Generic medicine List

S.#	Generic Name	S.#	Generic Name
1	Abemaciclib 150 mg	46	Dacarbazine 200 mg
2	Abiraterone acetate 250 mg	47	Dacomitinib 45 mg
3	Abiraterone Acetate 250mg	48	Dasatinib dasatinib
4	Abiraterone acetate 500 mg	49	Daunorubicin 20 mg
5	Acalabrutinib 10 mg	50	Decitabine 100mg
6	Acalabrutinib 60 mg	51	Denosumab 120 mg
7	Ado-Trastuzumab Emtansine 100 mg	52	Docetaxel (DTX or DXL) 120 mg
8	Ado-Trastuzumab Emtansine 100mg	53	Docetaxel (DTX or DXL) 20 mg
9	Ado-Trastuzumab Emtansine 160 mg	54	Docetaxel (DTX or DXL) 80 mg
10	Ado-Trastuzumab Emtansine 400mg	55	Doxorubicin 10 mg
11	Afatinib 40 mg	56	Doxorubicin 50 mg
12	Alectinib 150 mg	57	Durvalumab 500 mg
13	Alpelisib 150 mg	58	Eltrombopag 25 mg
14	Anastrozole 1 mg	59	Eltrombopag 50 mg
15	Apalutamide 60 mg	60	Enasidenib 50 mg
16	Atezolizumab 1200 mg	61	Enzalutamide 80 mg
17	Axitinib 5 mg	62	Enzalutamide mg
18	Azacitidine 100 mg	63	Epirubicin 10 mg
19	Bendamustine 100 mg	64	Epirubicin 50 mg
20	Bevacizumab 100 mg	65	Erdafitinib 4 mg
21	Bevacizumab 400 mg	66	Eribulin 1 mg/2mL
22	Bicalutamide 50 mg	67	Erlotinib 150 mg
23	Bleomycin 15 IU	68	Erythropoietin 10000 IU
24	Bortezomib 3.5 mg	69	Etoposide 100 mg
25	Cabazitaxel 60 mg	70	Everolimus 10mg
26	Cabozantinib 20 mg	71	Exemestane 25 mg
27	Cabozantinib 80 mg	72	Filgrastim 300 µg
28	Camrelizumab 200mg	73	Fludarabine 50 mg
29	Capecitabine 500 mg	74	Fluorouracil (5-FU, 5-fluorouracil) 250 mg
30	Capmatinib 40 mg	75	Fluorouracil (5-FU, 5-fluorouracil) 500 mg
31	Carboplatin 150 mg	76	Flutamide 250
32	Carboplatin 450 mg	77	Fulvestrant 250 mg
33	Carfilzomib 60mg	78	Gefitinib 250mg
34	Ceritinib 250mg	79	Gemcitabine 1000 mg
35	Cetuximab 100mg	80	Gemcitabine 200 mg
36	Cisplatin 10 mg	81	Goserelin 3.6 mg
37	Cisplatin 25 mg	82	Hydroxyurea 500 mg
38	Cisplatin 50 mg	83	Ibrutinib 140 mg
39	Crizotinib 250 mg	84	Ifosfamide 1000 mg
40	Cyclophosphamide 1g	85	Ifosfamide 1g
41	Cyclophosphamide (CP) 1000 mg	86	Ifosfamide 2000 mg
42	Cyclophosphamide (CP) 500 mg	87	Imatinib 100 mg
43	Cytarabine (ara-C) 100 mg	88	Imatinib 400 mg
44	Cytarabine (ara-C) 1000 mg	89	Ipilimumab 50 mg
45	Cytarabine (ara-C) 500 mg	90	Irinotecan 100 mg

BINOR Patients Welfare Society Bannu
Tender for FY 2026-27
Generic medicine List

S.#	Generic Name	S.#	Generic Name
91	Irinotecan 300 mg	137	Paclitaxel 100 mg
92	Irinotecan 40 mg	138	Paclitaxel 150 mg
93	Ivosidenib 250 mg	139	Paclitaxel 30 mg
94	kadcyla 160 mg	140	Paclitaxel 300 mg
95	Lapatinib (INN) 250 mg	141	Palbociclib 100 mg
96	Larotrectinib 100 mg	142	Palbociclib 125 mg
97	L-Asparaginase 10000 IU	143	Palbociclib 75 mg
98	Lenalidomide 10 mg	144	Pazopanib 200 mg
99	Lenalidomide 25 mg	145	Pazopanib 400 mg
100	Lenalidomide 5 mg	146	Pegaspargase
101	Lenvatinib 10 mg	147	Pegfilgrastim 6 mg
102	Lenvatinib 4 mg	148	Pegliposomal Doxorubicin 20 mg
103	Letrozole 2.5 mg	149	Pembrolizumab 100 mg
104	Leucovorin Calcium (Folinic acid) 100 mg	150	Pemetrexed 100 mg
105	Leucovorin Calcium (Folinic acid) 15 mg	151	Pemetrexed 500 mg
106	Leucovorin Calcium (Folinic acid) 50 mg	152	Pertuzumab 420 mg
107	Leuprorelin (Leuprolide) 11.25 mg	153	Pertuzumab/Trastuzumab 600 mg
108	Leuprorelin (Leuprolide) 3.75 mg	154	Polatuzumab vedotin 140 mg
109	Leuprorelin (Leuprolide) 7.5 mg	155	Pomalidomide 4mg
110	Liposomal Doxorubicin 20 mg	156	Ponatinib 15 mg
111	Lomustine mg	157	Ponatinib 45 mg
112	Lorlatinib 100 mg	158	Procarbazine 50mg
113	Mercaptopurine (6-MP) 50 mg	159	Ramucirumab 100 mg
114	Mesna 400mg	160	Recombinant Interleukin-2 3mg
115	Methotrexate (Amethopterin) 10 mg	161	Regorafenib 40 mg
116	Methotrexate (Amethopterin) 1000 mg	162	Rituximab 100 mg
117	Methotrexate (Amethopterin) 2.5 mg	163	Rituximab 1400 mg
118	Methotrexate (Amethopterin) 50 mg	164	Rituximab 500 mg
119	Methotrexate (Amethopterin) 500 mg	165	Ruxolitinib 15 mg
120	Mitomycin 10 mg	166	Ruxolitinib 5 mg
121	Mobocertinib 40 mg	167	Sacituzumab govitecan 180 mg
122	Nab-paclitaxel 100 mg	168	Selinexor 20 mg
123	Neratinib (INN)	169	Selpercatinib 40 mg
124	Nilotinib 150 mg	170	Sodium2-Mercaptoethanesulfonate 100 mg
125	Nilotinib 200 mg	171	Sorafenib 200 mg
126	Niraparib 100 mg	172	Sotorasib 120 mg
127	Nivolumab 10 mg	173	Sunitinib 12.5 mg
128	Nivolumab 100 mg	174	Sunitinib 25 mg
129	Nivolumab 40 mg	175	Sunitinib 50 mg
130	Obinutuzumab 1000 mg	176	Talazoparib 1 mg
131	Olaparib 150 mg	177	Tamoxifen 10 mg
132	Onco BC 6 6	178	Tamoxifen 20 mg
133	Oprelvekin(Recombinant Interleukin Eleven (IL-1	179	Temozolomide 100 mg
134	Osimertinib 80 mg	180	Temozolomide 20 mg
135	Oxaliplatin 100 mg	181	Temozolomide 250 mg
136	Oxaliplatin 50 mg	182	Thalidomide 100 mg

BINOR Patients Welfare Society Bannu

Tender for FY 2026-27

Generic medicine List

S.#	Generic Name	S.#	Generic Name
183	Tivozanib 1.34		
184	Topotecan 4 mg		
185	Trastuzumab 440 mg		
186	Trastuzumab 600 mg S/C		
187	Trastuzumab deruxtecan 100 mg		
188	Trifluridine/tipiracil (FTD–TPI) 15 mg		
189	Tucatinib 150 mg		
190	Venetoclax 10 mg		
191	Vinblastine 10 mg		
192	Vincristine 1 mg		
193	Vincristine 2 mg		
194	Vinorelbine 50 mg		
195	Zoledronic acid 4 mg		